Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function

Genes and Development

Volumn 18, Issue 21, 2004, Pages 2614-2626

  Keller, Charles ^a   Arenkiel, Benjamin R ^a   Coffin, Cheryl M ^a   El Bardeesy, Nabeel ^b   DePinho, Ronald A ^b   Capecchi, Mario R ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Alveolar rhabdomyosarcoma; Chromosome translocation; Fkhr; FoxO1A; Pax3; Pax3:Fkhr; Satellite cell

Indexed keywords

ARF PROTEIN; HYBRID PROTEIN; INK4 ARF PROTEIN; PROTEIN; TRP PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIRTH DEFECT; CARCINOGENESIS; CHILDHOOD CANCER; CHROMOSOME TRANSLOCATION; EMBRYO DEVELOPMENT; EMBRYONAL RHABDOMYOSARCOMA; FOXO1A GENE; FUSION GENE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE LOSS; HAPLOTYPE; HYBRID GENE; IMMUNOHISTOCHEMISTRY; INK4A ARF GENE; KNOCKIN GENE; MOUSE; MUSCLE CANCER; MUSCLE DEVELOPMENT; MYF6 GENE; NEWBORN; NONHUMAN; PAX3 FKHR GENE; PLEOMORPHIC RHABDOMYOSARCOMA; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; RHABDOMYOSARCOMA; SATELLITE CELL; SKELETAL MUSCLE; TRP53 GENE;

ADP-RIBOSYLATION FACTORS; ANIMALS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENETIC ENGINEERING; HUMANS; MICE; MICE, MUTANT STRAINS; MUSCLE, SKELETAL; MUTATION; MYOGENIC REGULATORY FACTORS; PAIRED BOX TRANSCRIPTION FACTORS; RHABDOMYOSARCOMA, ALVEOLAR; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA; MURINAE; MUS MUSCULUS;

EID: 7544243041     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.1244004     Document Type: Article

References (56)

1. Aguirre, A.J., Bardeesy, N., Sinha, M., Lopez, L., Tuveson, D.A., Horner, J., Redston, M.S., and DePinho, R.A. 2003. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes & Dev. 17: 3112-3126.
2. Anderson, M.J., Shelton, G.D., Cavenee, W.K., and Arden, K.C. 2001. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc. Natl. Acad. Sci. 98: 1589-1594.
3. Arenkiel, B.R., Gaufo, G.O., and Capecchi, M.R. 2003. Hoxb1 neural crest preferentially form glia of the PNS. Dev. Dyn. 227: 379-386.
4. Arndt, C.A. and Crist, W.M. 1999. Common musculoskeletal tumors of childhood and adolescence. New Eng. J. Med. 341: 342-352.
5. Ashfield, R., Enriquez-Harris, P., and Proudfoot, N.J. 1991. Transcriptional termination between the closely linked human complement genes C2 and Factor B: Common termination factor for C2 and c-myc? EMBO J. 10: 4197-4207.
6. Barr, F.G., Galili, N., Holick, J., Biegel, J.A., Rovera, G., and Emanuel, B.S. 1993. Rearrangement of the PAX3 paired box gene in the paediatric solid tumor alveolar rhabdomyosarcoma. Nat. Genet. 3: 113-117.
7. Bober, E., Lyons, G.E., Braun, T., Cossu, G., Buckingham, M., and Arnold, H.-H. 1991. The muscle regulatory gene, Myf-6, has a biphasic pattern of expression during early mouse development. J. Cell Biol. 113: 1255-1265.
8. Boulet, A.M. and Capecchi, M.R. 2004. Multiple roles of Hoxa11 and Hoxd11 in the formation of the mammalian forelimb zeugopod. Development 131: 299-309.
9. Braun, T. and Arnold, H.-H. 1995. Inactivation of Myf-6 and Myf-5 genes in mice leads to alterations in skeletal muscle development. EMBO J. 14: 1176-1186.
10. Cavenee, W.K. 2002. Muscling in on rhabdomyosarcoma. Nat. Med. 8: 1200-1201.
11. Cornelison, D.D. and Wold, B.J. 1997. Single-cell analysis of regulatory gene expression in quiescent and activated mouse skeletal muscle satellite cells. Dev. Biol. 191: 270-283.
12. Felix, C.A., Kappel, C.C., Mitsudomi, T., Nau, M.M., Tsokos, M., Crouch, G.D., Nisen, P.D., Winick, N.J., and Helman, L.J. 1992. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res. 52: 2243-2247.
13. Fleischmann, A., Jochum, W., Eferl, R., Witowsky, J., and Wagner, E.F. 2003. Rhabdomyosarcoma development in mice lacking Trp53 and Fos: Tumor suppression by the Fos protooncogene. Cancer Cell 4: 477-482.
14. Forster, A., Pannell, R., Drynan, L.F., McCormack, M., Collins, E.C., Daser, A., and Rabbitts, T.H. 2003. Engineering de novo reciprocal chromosomal translocations associated with M11 to replicate primary events of human cancer. Cancer Cell 3: 449-458.
15. Frascella, E., Toffolatti, L., and Rosolen, A. 1998. Normal and rearranged PAX3 expression in human rhabdomyosarcoma. Cancer Genet. Cytogenet. 102: 104-109.
16. Ginsberg, J.P., Davis, R.J., Bennicelli, J.L., Nauta, L.E., and Barr, F.G. 1998. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 58: 3542-3546.
17. Goulding, M., Sterrer, S., Fleming, J., Balling, R., Nadeau, J., Moore, K.J., Brown, S.D., Steel, K.P., and Gruss, P. 1993. Analysis of the Pax-3 gene in the mouse mutant splotch. Genomics 17: 355-363.
18. Greaves, M.F. and Wiemels, J. 2003. Origins of chromosome translocations in childhood leukaemia. Nat. Rev. Cancer 3: 639-649.
19. Green, J.A., Robertson, L.J., and Clark, A.H. 1993. Glutathione S-transferase expression in benign and malignant ovarian tumors. Br. J. Cancer 68: 235-239.
20. Grundy, R., Anderson, J., Gaze, M., Gerrard, M., Glaser, A., Gordon, A., Malone, M., Pritchard-Jones, K., and Michalski, A. 2001. Congenital alveolar rhabdomyosarcomam. Cancer 91: 606-612.
21. Gurney, J.G., Young Jr., J.L., Roffers, S.D., Smith, M.A., and Bunin, G.R. 1999. Soft tissue sarcomas. In Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995, National Cancer Institute, SEER Program, NIH Pub. No. 99-4649 (eds. S.M. Ries LAG et al.), pp. 111-124. National Cancer Institute, Bethesda, MD.
22. Hosaka, T., Biggs III, W.H., Tieu, D., Boyer, A.D., Varki, N.M., Cavenee, W.K., and Arden, K.C. 2004. Disruption of fork-head transcription factor (FOXO) family members in mice reveals their functional diversification. Proc. Natl. Acad. Sci. 101: 2975-2980.
23. Hsu, Y.T., Wolter, K.G., and Youle, R.J. 1997. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc. Natl. Acad. Sci. 94: 3668-3672.
24. Humphrey, G., Hazel, D.L., MacLennan, K., and Lewis, I. 1999. Expression of CD44 by rhabdomyosarcoma: A new prognostic marker? Br. J. Cancer 80: 918-921.
25. Iolascon, A., Faienza, M.F., Coppola, B., Rosolen, A., Basso, G., Della Ragione, F., and Schettini, F. 1996. Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma. Genes Chrom. Cancer 15: 217-222.
26. Jacks, T., Remington, L., Williams, B.O., Schmitt, E.M., Halachmi, S., Bronson, R.T., and Weinberg, R.A. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4: 1-7.
27. Jeffers, M., Schmidt, L., Nakaigawa, N., Webb, C.P., Weirich, G., Kishida, T., Zbar, B., and Vande Woude, G.F. 1997. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc. Natl. Acad. Sci. 94: 11445-11450.
28. Jonkers, J., Meuwissen, R., van der Gulden, H., Peterse, H., van der Valk, M., and Berns, A. 2001. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29: 418-425.
29. Keller, C, Hansen, M.S., Coffin, C.M., and Capecchi, M.R. 2004. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: Implications for alveolar rhabdomyosarcoma cell of origin. Genes & Dev. (this issue).
30. Kirkwood, T.B. 2002. p53 and ageing: Too much of a good thing? Bioessays 24: 577-579.
31. Kouraklis, G., Triche, T.J., Wesley, R., and Tsokos, M. 1999. Myc oncogene expression and nude mouse tumorigenicity and metastasis formation are higher in alveolar than embryonal rhabdomyosarcoma cell lines. Pediatric Res. 45: 552-558.
32. Lagutina, I., Conway, S.J., Sublett, J., and Grosveld, G.C. 2002. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors. Mol. Cell Biol. 22: 7204-7216.
33. Li, F.P. and Fraumeni Jr., J.F. 1969. Rhabdomyosarcoma in children: Epidemiologic study and identification of a familial cancer syndrome. J. Natl. Cancer Inst. 43: 1365-1373.
34. Li, J., Liu, K.C., Jin, F., Lu, M.M., and Epstein, J.A. 1999. Transgenic rescue of congenital heart disease and spina bifida in Splotch mice. Development 126: 2495-2503.
35. Mansour, S.L., Thomas, K.R., and Capecchi, M.R. 1988. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: A general strategy for targeting mutations to non-selectable genes. Nature 336: 348-352.
36. Margue, C.M., Bernasconi, M., Barr, F.G., and Schafer, B.W. 2000. Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene 19: 2921-2929.
37. Mark, H.F., Brown, S., Sun, C.L., Samy, M., and Afify, A. 1998. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 66: 59-63.
38. Moreira, A., Wollerton, M., Monks, J., and Proudfoot, N.J. 1995. Upstream sequence elements enhance poly(A) site efficiency of the C2 complement gene and are phylogenetically conserved. EMBO J. 14: 3809-3819.
39. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., and Roder, J.C. 1993. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl. Acad. Sci. 90: 8424-8428.
40. Nanni, P., Nicoletti, G., De Giovanni, C., Croci, S., Astolfi, A., Landuzzi, L., Di Carlo, E., Iezzi, M., Musiani, P., and Lollini, P.L. 2003. Development of rhabdomyosarcoma in HER-2/ neu transgenic p53 mutant mice. Cancer Res. 63: 2728-2732.
41. Nilsson, J.A. and Cleveland, J.L. 2003. Myc pathways provoking cell suicide and cancer. Oncogene 22: 9007-9021.
42. Odelberg, S.J., Kollhoff, A., and Keatin, M.T. 2000. Dedifferentiation of mammalian myotubes induced by msx1. Cell 103: 1099-1109.
43. Olson, E.N., Arnold, H.H., Rigby, P.W., and Wold, B.J. 1996. Know your neighbors: Three phenotypes in null mutants of the myogenic bHLH gene MRF4. Cell 85: 1-4.
44. Qualman, S.J., Coffin, C.M., Newton, W.A., Hojo, H., Triche, T.J., Parham, D.M., and Crist, W.M. 1998. Intergroup rhabdomyosarcoma study: Update for pathologists. Pediatr. Dev. Pathol. 1: 550-561.
45. Relaix, F., Polimeni, M., Rocancourt, D., Ponzetto, C., Schafer, B.W., and Buckingham, M. 2003. The transcriptional activator PAX3-FKHR rescues the defects of Pax3 mutant mice but induces a myogenic gain-of-function phenotype with ligand-independent activation of Met signaling in vivo. Genes & Dev. 17: 2950-2965.
46. Rodriguez, C.I., Buchholz, F., Galloway, J., Sequerra, R., Kasper, J., Ayala, R., Stewart, A.F., and Dymecki, S.M. 2000. High-efficiency deleter mice show that FLPe is an alternative to Cre-loxP [letter]. Nat. Genet. 25: 139-140.
47. Sharp, R., Recio, J.A., Jhappan, C., Otsuka, T., Liu, S., Yu, Y., Liu, W., Anver, M., Navid, F., Helman, L.J., et al. 2002. Synergism between INK4a/ARF inactivation and aberrant HGF/ SF signaling in rhabdomyosarcomagenesis. Nat. Med. 8: 1276-1280.
48. Sorensen, P.H., Lynch, J.C., Qualman, S.J., Tirabosco, R., Lim, J.F., Maurer, H.M., Bridge, J.A., Crist, W.M., Triche, T.J., and Barr, F.G. 2002. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J. Clin. Oncol. 20: 2672-2679.
49. Sorriano, P. 1999. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21: 70-71.
50. Summerbell, D., Halai, C., and Rigby, P.W. 2002. Expression of the myogenic regulatory factor Mrf4 precedes or is contemporaneous with that of Myf5 in the somitic bud. Mech. Dev. 117: 331-335.
51. Takahashi, Y., Oda, Y., Kawaguchi, K., Tamiya, S., Yamamoto, H., Suita, S., and Tsuneyoshi, M. 2004. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma. Mod. Pathol. 17: 660-669.
52. Tassabehji, M., Read, A.P., Newton, V.E., Patton, M., Gruss, P., Harris, R., and Strachan, T. 1993. Mutations in the PAX3 gene causing Waardenburg syndrome type 1 and type 2. Nat. Genet. 3: 26-30.
53. Tiffin, N., Williams, R.D., Shipley, J., and Pritchard-Jones, K. 2003. PAX7 expression in embryonal rhabdomyosarcoma suggests an origin in muscle satellite cells. Br. J. Cancer 89: 327-332.
54. Tomescu, O., Xia, S.J., Strezlecki, D., Bennicelli, J.L., Ginsberg, J., Pawel, B., and Barr, F.G. 2004. Inducible short-term and stable long-term cell culture systems reveal that the PAX3-FKHR fusion oncoprotein regulates CXCR4, PAX3, and PAX7 expression. Lab. Invest. 84: 1060-1070.
55. Tonin, P.N., Scrable, H., Shimada, H., and Cavenee, W.K. 1991. Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development. Cancer Res. 51: 5100-5106.
56. Wexler, L.H. and Helman, L.J. 1997. Rhabdomyosarcoma and the undifferentiated sarcomas. In Principles and practice of pediatric oncology (eds. P.A. Pizzo and D.G. Poplack), pp. 799-829. Lippincott-Raven, Philadelphia.